Bacteriocin-Producing Probiotic Lactic Acid Bacteria in Controlling Dysbiosis of the Gut Microbiota.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and potential therapeutic roles without primary human data or systematic review methodology.
PubMed 35651753 · doi:10.3389/fcimb.2022.851140
What was done
This narrative review synthesized literature on the mechanisms of bacteriocin-producing probiotic lactic acid bacteria and their potential roles in correcting gut dysbiosis and managing conditions such as chronic infections, inflammatory bowel disease, obesity, and cancer.
What was found
The abstract reports no numerical data or quantitative outcomes. It describes the mechanism of bacteriocins as cationic antimicrobial peptides that kill closely related and pathogenic bacteria (including Listeria, Clostridium, and Salmonella) through pore formation and cytoplasmic leakage, alongside host immune and microbiota modulation.
Why it matters
It highlights the conceptual value of peptide-mediated targeted pathogen inhibition by probiotic strains as an alternative or adjunct strategy for gut microbiome modulation.
Limits
As a narrative review, it lacks primary empirical data, quantitative effect estimates, and systematic search criteria. Clinical efficacy, optimal dosing, strain specificity, and human in vivo outcomes are not reported in the abstract.
Cited by
- supports Certain bacteria in the microbiome secrete antimicrobial peptides that function as natural antibiotics to inhibit competing bacterial species.